Roche Upbeat On Recent Launches, Oncology And Actemra To Drive Growth Through Mid-Term

Roche presented a mixed sales picture across regions and products in a first quarter 2012 earnings call. Management highlighted a busy regulatory quarter with two new NME launches and five positive Phase III trials and filings, but also reported generic and competitive threats to key products.